Peptides DB
Research-centric peptide and protocol reference hub
Study 61 of 62Semaglutide literaturePharmacoepidemiology and drug safety · Observational2025

Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.

Only 8.2% of patients using semaglutide and tirzepatide had documented use of compounded formulations in their medical records, indicating a significant gap in awareness among healthcare providers.

Read at Pharmacoepidemiology and drug safetyAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
13
Preclinical
38
Observational · this one
2
Open-label
2
Randomised
7
Reviews

Summary and findings

This study estimated the documentation rate of compounded semaglutide and tirzepatide in US primary care, analyzing data from January 1, 2021, to December 31, 2024. Among 153,044 patients, 8.2% used compounded formulations, which showed an increasing trend over time. Users of compounded formulations had longer therapy durations compared to those on brand-name drugs.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
8.2% of patients used compounded formulations, n=153044.2025

Abstract

The authors’ words, as Pharmacoepidemiology and drug safety supplied them

<h4>Purpose</h4>Large telehealth companies and smaller aesthetic medicine providers used compounded semaglutide and tirzepatide to meet consumer demand for these drugs during their shortages. In this study, we estimate the documentation rate of compounded formulations of these drugs in the US primary care and characterize differences between users of compounded and brand-name formulations of these drugs.<h4>Methods</h4>We conducted a retrospective cohort study using data from the American Family Cohort, a nationwide US database of electronic health records from primary care practices, spanning January 1, 2021, to December 31, 2024. Patients with documented semaglutide and/or tirzepatide use were included. Brand-name drug prescriptions were identified from structured data; compounded formulation use was identified from clinical notes. Outcomes included the proportion of patients using compounded formulations and their characteristics.<h4>Results</h4>Among 153 044 included patients (64.0% female, mean age 55.0 years), 8.2% used compounded formulations, which made up an increasing share of semaglutide and tirzepatide use over time. Users of compounded formulations had longer mean therapy durations (compounded only: 10.0 months vs. brand-name only: 7.8 months) and were more likely to be female, non-Hispanic White, nondiabetic, and to live in areas of lower socioeconomic deprivation compared to patients who used only brand-name drugs.<h4>Conclusions</h4>Between January 2021 and December 2024, documentation of compounded semaglutide and tirzepatide use in US primary care settings appeared lower than surveys reporting that approximately 23% of patients using these medications received them from compounders. This suggests that many patients may access these medications outside of coordinated care.<h4>Plain language summary</h4>During drug shortages from 2022 to 2024, many patients turned to compounded formulations of popular weight-loss medications semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) made by specialty pharmacies. We analyzed medical records from over 153 000 patients across the United States who used these medications to understand how often primary care doctors knew their patients were using compounded formulations. We found that only 8.3% of patients had documented use of compounded formulations in their medical records, far lower than previous surveys suggesting 23% of users get these medications from nontraditional sources like telehealth companies or aesthetic clinics. Patients using compounded formulations were more likely to be white, female, nondiabetic, and live in wealthier areas compared to those using brand-name versions. They also used the medications for longer periods. This gap between documented use and actual use suggests many patients are getting these medications outside their regular healthcare system, which could create safety concerns since doctors may not know about all the medications their patients are taking or be able to monitor for side effects properly.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Semaglutide corpus

BGLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.International journal of cardiology · 2026 · n=7326 · HR 0.655, 95% CI 0.508-0.844, p=0.001.HumanDGLP-1s and criminality: US trial will test whether semaglutide can fight crime.BMJ (Clinical research ed.) · 2026—DThe pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.reviewBCardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.Journal of diabetes and metabolic disorders · 2026 · n=271685 · 4.6% primary composite outcome incidence in tirzepatide group vs. 5.5% in semaglutide group, ARD -0.9%, 95% CI -1.01 to -0.77, HR 0.9, 95% CI 0.92─0.96.HumanBWeight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.Clinical obesity · 2023 · 30% TWL and 12 kg/m² BMI reduction for SG at 12 months, p < 0.001.HumanDSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · 2026 · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.review